Perampanel: all 77 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Senicapoc and Perampanel for Newly Diagnosed GlioblastomaRecruitingNCT07284069Early Phase 1
• PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac ArrestRecruitingNCT06401707Phase 2
• Fycompa in Catamenial EpilepsyTerminatedNCT05201703Phase 4Results posted
• Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal EpilepsyTerminatedNCT04650204Phase 4Results posted
• Effect of Perampanel on Peritumoral Hyperexcitability in HGGCompletedNCT04497142Phase 1/2Results posted
• Perampanel Titration and Cognitive EffectsTerminatedNCT04417907Phase 4Results posted
• A Study of Intravenous Perampanel in Japanese Participants With EpilepsyCompletedNCT03754582Phase 2Results posted
• Effects of Perampanel on Neurophysiology Test PerimetersCompletedNCT03653741Phase 4Results posted
• Fycompa Titration Intervals and Effects on Retention RateCompletedNCT03457129Phase 4Results posted
• Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic SeizuresCompletedNCT03288129Phase 4Results posted
• Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)CompletedNCT03201900Phase 3Results posted
• Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With EpilepsyCompletedNCT02914314Phase 2Results posted
• Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic SeizuresCompletedNCT02849626Phase 3Results posted
• Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut SyndromeTerminatedNCT02834793Phase 3Results posted
• Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary GeneralizationCompletedNCT02726074Phase 4Results posted
• An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy SubjectsCompletedNCT02427607Phase 3Results posted
• Perampanel in Seizure Patients With Primary Glial Brain TumorsCompletedNCT02363933Phase 4Results posted
• Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol DependenceCompletedNCT02120365Phase 1/2Results posted
• Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor FluctuationsTerminatedNCT01634360Phase 2Results posted
• A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset SeizuresCompletedNCT01618695Phase 3Results posted
• Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic DrugsCompletedNCT01527006Phase 2Results posted
• A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic SeizuresCompletedNCT01393743Phase 3Results posted
• A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in AdolescentsCompletedNCT01161524Phase 2Results posted
• A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)CompletedNCT00903786Phase 2Results posted
• An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)CompletedNCT00849212Phase 2Results posted
• Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial SeizuresCompletedNCT00735397Phase 3Results posted
• Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial SeizuresCompletedNCT00700310Phase 3Results posted
• Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial SeizuresCompletedNCT00699972Phase 3Results posted
• To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial SeizuresCompletedNCT00699582Phase 3Results posted
• Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)CompletedNCT00592904Phase 2/3Results posted
• Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)CompletedNCT00592774Phase 2Results posted
• Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECTTerminatedNCT00566462Phase 2Results posted
• Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor FluctuationsTerminatedNCT00505622Phase 3Results posted
• An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic NeuropathyCompletedNCT00505284Phase 2/3Results posted
• A Study of E2007 In Patients With Parkinson's DiseaseTerminatedNCT00427011Phase 2Results posted
• Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial SeizuresCompletedNCT00416195Phase 2Results posted
• 4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial SeizuresCompletedNCT00368472Phase 2Results posted
• Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsCompletedNCT00368108Phase 3Results posted
• A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsTerminatedNCT00360412Phase 3Results posted
• Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsTerminatedNCT00360308Phase 3Results posted
• A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor FluctuationsCompletedNCT00165789Phase 2Results posted
• Efficacy and Safety Study of E2007 in Migraine ProphylaxisCompletedNCT00154063Phase 2Results posted
• Bioequivalence Assessment Between Two Perampanel Oral Suspension FormulationsCompletedNCT06969963Phase 1
• Bioequivalence Study of Perampanel Tablets 10 mgCompletedNCT06450236Phase 1
• Bioequivalence Study of Perampanel Tablets 12 mgCompletedNCT06450223Phase 1
• Efficacy and Safety of Perampanel in the Treatment of Refractory Status EpilepticusTerminatedNCT05684978Phase 4
• A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic SeizuresCompletedNCT05533814Phase 4
• Post-stroke Epilepsy: Primary Prophylaxis StudyStatus unknownNCT04858841Not applicable
• Perampanel in Focal Status EpilepticusTerminatedNCT04309721Phase 3
• Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PERStatus unknownNCT04118829Phase 4
• A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood EpilepsyActive, not recruitingNCT04015141Phase 2
• Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral SclerosisCompletedNCT03793868Early Phase 1
• Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With EpilepsyCompletedNCT03780907Phase 2
• Efficacy and Safety of Perampanel in Combination in Glioma-refractory EpilepsyWithdrawnNCT03636958Not applicable
• Pharmacokinetic Study of Perampanel in Chinese Healthy SubjectsCompletedNCT03424564Phase 1
• Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese SubjectsCompletedNCT03399734Phase 1
• Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis PatientsTerminatedNCT03377309Phase 2
• Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy SubjectsCompletedNCT03376997Phase 1
• A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT03020797Not applicable
• Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)CompletedNCT03019419Phase 2
• Effects of Perampanel on Cognition and Electroencephalography in Patients With EpilepsyCompletedNCT02900755Phase 4
• Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.TerminatedNCT02727101Phase 4
• An Efficacy/Safety Study of Perampanel for Reducing Essential TremorStatus unknownNCT02668146Phase 2
• Fycompa in Subjects With Small Fiber Neuropathy (SFN)Status unknownNCT02511873Phase 2
• A Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy SubjectsCompletedNCT02279485Phase 1
• To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset SeizuresWithdrawnNCT02220972Phase 4
• Safety and Tolerability of Perampanel in Cervical DystoniaCompletedNCT02131467Phase 1/2
• An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male SubjectsCompletedNCT02116907Phase 1
• A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy SubjectsCompletedNCT02020486Phase 1
• A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With PerampanelCompletedNCT01531920Phase 1
• Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy SubjectsCompletedNCT01396590Phase 1
• Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy SubjectsCompletedNCT01396577Phase 1
• A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy SubjectsCompletedNCT01240187Phase 1
• A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period DyskinesiasCompletedNCT01172379Phase 2
• The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor FluctuationsWithdrawnNCT00451633Phase 2
• The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsCompletedNCT00286897Phase 3
• E2007 Given as Adjunctive Therapy in Patients With Refractory Partial SeizuresCompletedNCT00144690Phase 2

← Perampanel overview